LLY
RHHBY
A blood test tries to make Alzheimer’s diagnosis less brutal
Roche got European CE Mark approval for Elecsys pTau217, a blood test built to help spot amyloid pathology linked to Alzheimer’s disease earlier in patients with signs of cognitive decline. Translation: instead of leaning so hard on PET scans and spinal taps, doctors may get a simpler first pass from a blood draw. Nice for patients. Also nice for Roche’s diagnostics business, which loves anything that can move from niche to routine.
Why investors should care
The test matters because Alzheimer’s diagnosis is often slow, expensive, and awkwardly dependent on specialized tools that many clinics don’t have lying around. Roche says the same cutoff values can be used in both primary and secondary care, which makes the assay feel more like a mainstream workflow tool and less like a lab science demo.
- A positive result suggests a high likelihood of amyloid pathology
- A negative result points to a low likelihood, potentially avoiding extra invasive tests
- Indeterminate results still need follow-up, because medicine, like life, loves a gray area
Lilly gets a side quest
Eli Lilly collaborated with Roche on the test, so this isn’t just Roche doing a solo victory lap. For Lilly, the tie-in reinforces its neuroscience story while it keeps pushing deeper into Alzheimer’s-related treatment and diagnosis. The company also said it could pursue U.S. approval later this year, which means this could go from Europe-only to a much bigger commercial lane if regulators eventually say yes.
Big picture
Diagnostics rarely get the same hype as blockbuster drugs, but this is exactly the kind of product that can quietly become a workhorse. If Roche can expand the test broadly, it could help pull Alzheimer’s care earlier into routine medicine — and that’s the sort of shift that can turn a scientific win into a recurring revenue stream.